88 results
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
25 Apr 24
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
6:46am
for a majority of commercially covered lives for ZURZUVAE in the treatment of women with postpartum depression (PPD) without step therapy or complex prior … and expect formulary discussions to continue over the course of 2024.
In the first quarter of 2024, the majority of prescriptions were covered
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
17 Apr 24
Regulation FD Disclosure
6:35am
, and there were no new safety signals observed. A total of 48 participants experienced treatment emergent adverse events (TEAEs). The vast majority of TEAES
8-K
EX-99.1
wzrn3n2
14 Feb 24
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
SC TO-I
EX-99
o8xewmc
23 Jan 24
Issuer tender offer statement
8:13am
SC TO-I
EX-99
r336r9zvi
23 Jan 24
Issuer tender offer statement
8:13am
PRE 14A
blhdwkksqph9lwj
8 Dec 23
Preliminary proxy
8:30am
424B5
jdl0tb0qn k9z4o9o
7 Nov 23
Prospectus supplement for primary offering
7:29am
8-K
EX-3.1
jobj9 eynj8lbu68qd0
16 Jun 23
Departure of Directors or Certain Officers
4:06pm